Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 1

1(20.0%)

Early Phase 1

1(20.0%)

5Total

Phase 2(3)

Phase 1(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04709705Phase 2Completed

DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)

Role: lead

NCT05771831Phase 2Completed

Thrombosomes® in Acute Thoracic Aortic Dissections

Role: collaborator

NCT04619108Unknown

Thrombosomes for Expanded Access Use

Role: lead

NCT04631211Phase 2Terminated

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Role: lead

NCT03394755Phase 1Completed

Thrombosomes® in Bleeding Thrombocytopenic Patients

Role: lead

NCT02223117Early Phase 1Completed

Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)

Role: lead

All 6 trials loaded